Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.
Wen Wee(Roswell Park Comprehensive Cancer Center), Eliel Bayever(Knite (United States)), Carey K. Anders(Duke University), Catherine W. Reddick(Knite (United States)), Andrea E. Wahner Hendrickson(Mayo Clinic in Arizona), Luis Rojas‐Espaillat(Avera McKennan Hospital & University Health Center), Yonina R. Murciano‐Goroff(Memorial Sloan Kettering Cancer Center), Gregory P. Adams(University of Colorado Denver), Gerardo Colón‐Otero(Jacksonville College), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Babar Bashir(Thomas Jefferson University), Cesar A. Perez(Sarah Cannon), Douglas Orr(Mary Crowley Cancer Research Center), Cara Mathews(Brown University), Elizabeth M. Swisher(University of Washington), Erika Hamilton(Sarah Cannon)
Cited by 3
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Targeting HER2-positive breast cancer: advances and future directions
|Nature Reviews Drug Discovery|2022|1k